News | Radiation Therapy | August 22, 2019

Surging Demand for Image-guided, Stereotactic Radiation Therapy Driving Fiducial Marker Growth

New market report projects worldwide revenue for fiducial markers to pass $100 million by end of 2019

Surging Demand for Image-guided, Stereotactic Radiation Therapy Driving Fiducial Marker Growth

August 22, 2019 — As fiducial markers gain traction in parallel to rising incidences of various cancer affecting lung, prostate, abdomen and kidney, the growth potential of the fiducial markers market is set to witness a considerable rise. Total worldwide sales are anticipated to surpass $100 million by the end of 2019, according to a new study by Fact.MR, registering a significant upswing from $93.9 million in 2018.

The escalating demand for fiducial markers can be accredited to:

As per the study, the adoption of fiducial markers for prostate cancer has been seeing a persistent increase, driven by their ability to aid in seamless target precision. Thus, rising adoption of fiducial markers as an effective tool for use in case of radiation treatment is fostering its popularity.

Use of fiducial markers for prostate cancer is on a steep rise by virtue of its effectiveness in individualizing patient care in advance detection, diagnosis and treatment. Furthermore, adoption of fiducial markers to address rising incidences of breast cancer is also proliferating according to the study, wherein markers are implanted in the target area to mitigate the risk of cancer recurrence.

According to the study, pure gold fiducial markers will outsell all other product types in 2019, with an estimated valuation worth $60 million by the end of 2019. Greater reliability and superior stability are the prime factors responsible for escalating demand for pure gold fiducial markers. Another key factor fueling their growth in the global market is the ability of pure gold fiducial markers to provide high-quality resolution.

While pure gold fiducial markers continue to be profitable, demand for metal-based fiducial markers is also foreseen to scale new heights, owing to their ability to provide superior accuracy in target delivery of radiation. Among all end-users — including hospitals, radiotherapy centers and cancer research centers — sales of fiducial markers are expected to witness a notable uptick in the radiotherapy centers with an anticipated valuation surpassing $39 million this year. According to Fact.MR, radiotherapy centers will look to use the markers to treat various forms of cancer or malignant tumors.

According to the report, North America continues to show significant opportunities for the manufacturers of fiducial markers, with the U.S. leading global demand. The fiducial markers market landscape shows a monopoly of leading players with established brand images and significant product portfolios. Diversification and expansion of existing product lines with new additions remain the key focus areas of the key players.

 The report states that leading players in the fiducial markers market are also investing in extensive research and development to foster seamless product development. Expansion of the customer base through product marketing via online portals is another significant approach adopted by the well-established players in the fiducial markers market.

The report presents actionable insights and opportunity assessment in the fiducial markers market for the forecast period of 2018- 2028. The report predicts market expansion at a compound annual growth rate (CAGR) of over 9 percent through 2028.

Access the full report here.

For more information:

Related Content

Newly released study results present a strong case for lung cancer screening in New Zealand — particularly for Māori whose mortality rates are between three and four times higher than other ethnic groups.

Image courtesy of Siemens Healthineers

News | Lung Imaging | September 30, 2020
September 30, 2020 — Newly released study results present a strong case for...
he Centers for Medicare and Medicaid Services (CMS) published the “Specialty Care Models to Improve Quality of Care and Reduce Expenditures (CMS-5527)” final rule.

Getty Images

News | Radiation Oncology | September 29, 2020
September 29, 2020 — On Sept.
Important milestone demonstrates the unrivalled experience, technological innovation and global market leadership of IBA and its clinical partners
News | Proton Therapy | September 25, 2020
September 25, 2020 — IBA (Ion Beam Applications SA) announced that more than 100,000 patients have now been treated w
Philips Azurion Lung Edition supports high precision diagnosis and minimally invasive therapy in one room
News | Lung Imaging | September 21, 2020
September 21, 2020 — Philips introduced...
Final rule includes mandatory participation for nearly 1,000 practices and does not allow sufficient time for transition

Getty Images

News | Radiation Oncology | September 21, 2020
September 21, 2020 — In response to the September 18 ...
According to a new report published by P&S Intelligence, the global radiotherapy market is expected to expand from $7.2M in 2019 to $17M by 2030.

Image courtesy of Accuray

Feature | Radiation Therapy | September 21, 2020 | By Melinda Taschetta-Millane
According to a...
Breast cancer patients whose disease has spread to their brains fare better if their metastases are picked up before they begin to cause symptoms, according to a study presented at the 12th European Breast Cancer Conference.

Getty Images

News | Breast Imaging | September 21, 2020
September 21, 2020 — Breast cancer patients whose disease has spread to their brains fare better if their metastases
Data from latest research presented at the ESMO Virtual Congress 2020 suggests COVID-19 pandemic halts cancer care and damages oncologists' wellbeing

Getty Images

News | Coronavirus (COVID-19) | September 17, 2020
September 17, 2020 — Delays and cancellation of cancer treatments and other safety measures undertaken to minimize th
Varian Drives Next Evolution of Proton Treatment Planning with Eclipse v16.1
News | Treatment Planning | September 15, 2020
September 15, 2020 — Varian announced it has received FDA 510(k) clearance for its Eclipse v16.1 treatment planning s